Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Additional DMF
Japanese DMF
Chinese DMF
Korean DMF
Injectable Forms
Yes
No

Elagolix sodium

CAS No.

832720-36-2

Reference product

Polymorphic form

Amorphous form

Therapeutic Area

Genito-urinary system & sex hormones

Status

Pipeline

EU DMF readiness

early development

US DMF readiness

early development

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK